Cargando…

Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis

Detalles Bibliográficos
Autores principales:	Zuo, Ling, Ao, Guangyu, Wang, Yushu, Gao, Ming, Qi, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438996/ https://www.ncbi.nlm.nih.gov/pubmed/34534563 http://dx.doi.org/10.1016/j.jinf.2021.09.003

Ejemplares similares

Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis
por: Gao, Ming, et al.
Publicado: (2023)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022)

Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022)

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2022)

The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2023)

The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2022)

The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis
por: Luo, Jie, et al.
Publicado: (2023)

Risk factors for mortality in hemodialysis patients with COVID-19: a systematic review and meta-analysis
por: Wang, Fengping, et al.
Publicado: (2021)

Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community
por: Iqbal, Leena, et al.
Publicado: (2021)

Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis
por: Tai, Yu-Lin, et al.
Publicado: (2023)

Bamlanivimab Decreases Severe Outcomes of SARS-CoV-2 Infection in Patients With Antineutrophil Cytoplasmic Antibody Vasculitis
por: Ghosh, Jyotsna, et al.
Publicado: (2021)

Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona
por: Dale, Ariella P., et al.
Publicado: (2021)

Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis
por: Wang, Yushu, et al.
Publicado: (2021)

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients
por: Jan, Muhammad Y., et al.
Publicado: (2021)

Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance
por: Guigon, Aurélie, et al.
Publicado: (2022)

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
por: Pommeret, F., et al.
Publicado: (2021)

The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2021)

Real World Utilization of Bamlanivimab at a Rural Community Hospital
por: Leavitt, Rachael, et al.
Publicado: (2021)

The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis
por: Wang, Yushu, et al.
Publicado: (2021)

BAMLANIVIMAB-INDUCED GUILLAIN-BARRÉ SYNDROME
por: PALAGUACHI, GLADYS, et al.
Publicado: (2021)

500. A Real-World Cohort Study of Bamlanivimab Versus Bamlanivimab-Etesevimab for Non-severe COVID-19
por: Monday, Lea, et al.
Publicado: (2021)

Bamlanivimab: Guillain-Barre syndrome: case report
Publicado: (2021)

Bamlanivimab: New-onset seizures: case report
Publicado: (2022)

Incidence and mortality rates of acute ischemic stroke in hospitalized patients in the United States
por: Ramphul, Kamleshun, et al.
Publicado: (2021)

The role of heparin in reducing in-hospital complications and three-month mortality rates in hospitalized COVID-19 patients
por: Calabretta, F., et al.
Publicado: (2022)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

Bamlanivimab infusion experience at one academic emergency department
por: Yoo, Michael J., et al.
Publicado: (2022)

Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
por: Destras, Grégory, et al.
Publicado: (2021)

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
por: Chen, Peter, et al.
Publicado: (2021)

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
por: Corwin, Douglas S, et al.
Publicado: (2021)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
por: Bariola, J Ryan, et al.
Publicado: (2021)

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
por: Chew, Kara W., et al.
Publicado: (2022)

Orders of Magnitude Change in Phenotype Rate Caused by Mutation
por: Ao, Ping
Publicado: (2007)

Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals
por: Quenzer, Faith C., et al.
Publicado: (2022)

Temporal variation, socioeconomic status, and out‐of‐hospital deaths as factors that influence mortality rates among hospitalized COVID‐19 patients receiving ACEIs/ARBs
por: Aftab, Owais M., et al.
Publicado: (2022)

Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis
por: Gao, Ya, et al.
Publicado: (2020)

Lower mortality rates in those living at moderate altitude
por: Burtscher, Martin
Publicado: (2016)

Drinking no-links to the severity of COVID-19: a systematic review and meta-analysis
por: Liu, Ming, et al.
Publicado: (2020)

542. Use of Bamlanivimab in Cancer Patients with Mild-to-Moderate COVID-19
por: Brock, Patricia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b0026mbkacm4fskuh63cvcgh2c